Financial Data and Key Metrics Changes - The company reported revenues of $190,058 for Q1 2026, representing a 34% increase compared to $142,227 in Q1 2025, primarily driven by increased portal fees and services related to equity securities [3][4] - Operating loss was approximately $3.3 million in Q1 2026, compared to an operating loss of approximately $2.5 million in Q1 2025 [4] - Loss per share improved to $1.27 from $5.10 in the same period last year [4] Business Line Data and Key Metrics Changes - The significant revenue increase was attributed to one issuer, which accounted for 73% of total revenues, successfully raising approximately $5 million during the quarter [3][4] Market Data and Key Metrics Changes - The company is focusing on integrating blockchain, digital assets, and crypto with traditional finance, indicating a strategic shift towards decentralized finance (DeFi) [6] Company Strategy and Development Direction - The company is committed to building a stronger, scalable business model, moving away from equity-based consulting revenue [5] - Establishment of a crypto advisory board and a game advisory board to enhance engagement and drive long-term growth [6] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the first quarter results, highlighting solid performance in core business and a strategic vision taking shape [5] - The company aims to lead in private market opportunities and direct investment opportunities for investors through innovation in blockchain and digital assets [6] Other Important Information - As of July 31, 2025, the company had cash and cash equivalents of approximately $4.6 million [4] Q&A Session Summary - The Q&A session was conducted but no specific questions or answers were documented in the provided content [8]

Summary of SPS Commerce 2025 Investor Day Company Overview - **Company**: SPS Commerce (NasdaqGS:SPSC) - **Industry**: Supply Chain Management and Retail Technology - **Headquarters**: Minneapolis, Minnesota - **Employee Count**: Approximately 3,000 employees, with half based in the Minneapolis-St. Paul area [2][3] Core Business Model - SPS Commerce operates a cloud-based network connecting retailers, suppliers, and third-party logistics providers to facilitate supply chain information exchange and collaboration [2][3] - The company serves three main market segments: retailers, suppliers, and third-party logistics providers [3] Growth Strategy - The company emphasizes the importance of network connections to enhance supply chain efficiency, sales growth, and margin improvement [3][4] - SPS Commerce aims to leverage its network to provide value-added applications, including fulfillment and revenue recovery, which are increasingly integrated into the network [6][8] - The company has identified a total addressable market (TAM) of $6.5 billion in the U.S. and over $11 billion globally, with plans to expand its customer base from 50,000 to 275,000 [16][17] Market Dynamics - The pandemic accelerated the adoption of omnichannel initiatives and dropship e-commerce, leading to increased customer count and average revenue per customer [9][11] - Current market conditions show a stabilization of omnichannel initiatives and a slowing customer count growth, attributed to macroeconomic uncertainties [12][14] Product Strategy - SPS Commerce focuses on collaboration and automation within the supply chain, with a strong emphasis on data availability to enhance customer collaboration [25][26] - The company employs a "build, buy, and partner" strategy to expand its product offerings, including recent acquisitions like Carbon6 and SupplyPike [29][30] - New product offerings include a revenue recovery solution and a performance management platform for retailers and suppliers to collaborate effectively [40][49] Go-to-Market Strategy - SPS Commerce's go-to-market strategy is centered around retail programs that facilitate supplier onboarding and compliance with retailer requirements [74][75] - The company maintains a high win rate of approximately 70% in securing new customers, primarily through its differentiated retail programs [76][78] Future Outlook - The company anticipates long-term growth driven by increased supply chain collaboration needs and the emergence of new consumer brands [14][15] - SPS Commerce is committed to continuous investment in technology and product development to enhance its network and customer offerings [50][51] Key Takeaways - SPS Commerce is well-positioned to capitalize on the growing demand for supply chain technology and collaboration solutions, with a robust network and a clear growth strategy [14][16] - The company's focus on data-driven insights and network-led growth presents unique opportunities for upselling and cross-selling to existing customers [20][21]

Summary of McKesson 2025 Investor Day Company Overview - **Company**: McKesson Corporation (NYSE: MCK) - **Event**: 2025 Investor Day held on September 23, 2025 - **Focus**: The presentation highlighted McKesson's growth strategy, innovation, and commitment to improving healthcare access and outcomes for patients [10][11][12] Core Industry Insights - **Healthcare Industry**: McKesson operates within the healthcare services sector, focusing on pharmaceutical distribution, oncology, and biopharma services. - **Market Dynamics**: The healthcare landscape is evolving with increasing demand for innovative therapies, personalized care, and advancements in technology and AI [19][20][76] Key Strategic Pillars 1. **People and Culture**: Emphasis on attracting and nurturing talent to drive productivity and innovation [21][22] 2. **Oncology and Multi-Specialty Services**: Continued investment in oncology services, which represent a significant area of growth and complexity in healthcare [24][25] 3. **North American Pharmaceutical Distribution**: Strengthening core distribution capabilities, which account for over one-third of pharmaceuticals in the U.S. with 99.9% order accuracy [30][72] 4. **Portfolio Modernization**: Ongoing evaluation and optimization of the business portfolio to align with strategic goals and enhance shareholder value [33][55] Financial Performance - **Growth Metrics**: Expected compounded growth rate of 10% in adjusted operating profit and 17% in adjusted earnings per diluted share for fiscal 2026 [18] - **Cash Flow Generation**: Strong cash flow has been utilized for organic and inorganic growth investments [15][54] Innovations and Technology - **AI and Automation**: Investments in advanced technologies to improve operational efficiency and patient outcomes [20][85] - **Supply Chain Resilience**: Focus on maintaining a robust supply chain to mitigate drug shortages and ensure medication access [88] Recent Developments - **Acquisitions**: Completed acquisition of Prism Vision to expand into retinal care, leveraging oncology expertise [27] - **Separation of Medical Surgical Segment**: Planned separation to enhance strategic focus and operational efficiency, expected to be completed by 2027 [59][58] Market Opportunities - **Aging Population**: Increasing demand for medications due to an aging demographic and rising chronic diseases [76] - **Specialty Pharmaceuticals**: Specialty drugs, particularly in oncology, are driving market growth, with significant investments planned in this area [78] Customer Relationships - **Strategic Partnerships**: Building strong relationships with key customers like Walmart and HCA Healthcare to enhance service delivery and patient access [89][91] Conclusion - **Future Outlook**: McKesson is positioned for sustained growth through strategic investments, a focus on innovation, and a commitment to improving healthcare outcomes for all [40][41]

ResMed Conference Call Summary Company Overview - **Company**: ResMed (NYSE:RMD) - **Industry**: Digital health and medical devices, focusing on sleep health, breathing health, and healthcare technology delivered at home - **Headquarters**: San Diego, California - **Founded**: 1989 - **Market Presence**: Sold 30 million cloud-connectable medical devices in 140 countries, with 23 billion nights of respiratory medical data collected [5][6] Core Strategies and Goals - **ResMed 2030 Strategy**: Aims to improve 500 million lives by 2030 through innovative products and services [6][7] - **Recent Achievements**: Changed 154 million lives in the last 12 months with devices and software [7] - **Product Development**: Focus on creating the smallest, quietest, and most comfortable devices, with a strong emphasis on cloud connectivity and intelligence [7][10] Financial Performance - **Free Cash Flow**: Generated over $1.7 billion in free cash flow in the last 12 months [9] - **Gross Margin Improvement**: Achieved 230 basis points year-on-year gross margin accretion in Q4 and 150 basis points quarter-on-quarter [9][10] - **Net Operating Profit Margins**: Currently in the range of 33-34% [10] Innovation and Product Development - **New Products**: Launched innovative products like the AirTouch N30i and AirFit F40, incorporating fabric into patient interfaces [11] - **Acquisitions**: Acquired Ectosense for its home sleep testing technology and Virtuox for home sleep apnea testing [12][57] - **Research Utilization**: Leveraging 23 billion nights of data to improve products and contribute to peer-reviewed research [13][14] Market Dynamics and Competitive Landscape - **Tariff Relief**: ResMed products benefit from tariff relief under the Nairobi Protocol, ensuring no tariffs on products made in various locations [12] - **Competitor Landscape**: Competitors have been affected by recalls, but ResMed remains confident in its market position and growth potential [47][48] - **Market Growth**: The device market is expected to grow mid-single digits, with ResMed aiming to exceed this through demand generation efforts [58] Patient Engagement and Adherence - **Adherence Rates**: Connected devices have increased adherence from 50% to 73%, and with app usage, adherence can reach 87% [14][20] - **GLP-1 Drug Impact**: Patients on GLP-1 weight loss drugs are 11% more likely to start CPAP therapy and show higher resupply rates [24][25] - **Patient Empowerment**: Focus on educating patients about access to equipment and the importance of adherence to therapy [20][23] Research and Development - **Investment in R&D**: ResMed invests 6-7% of revenues back into research and development to drive innovation [55] - **Future Growth**: Aiming for double-digit basis point improvements in gross margins annually through supply chain optimization and product innovation [63][64] Conclusion - ResMed is positioned as a leader in the digital health space, with a strong focus on innovation, patient engagement, and financial performance. The company is actively working to expand its market presence and improve patient outcomes through its 2030 strategy and ongoing product development initiatives.

Summary of Sanofi 2025 Conference Call Company Overview - **Company**: Sanofi (NasdaqGS:SNY) - **Date**: September 23, 2025 Key Points Industry and Market Dynamics - The year has been challenging for the pharmaceutical industry, with significant advancements in the pipeline but setbacks in specific drug readouts, particularly Itapecamab, which had mixed results [4][6] - The CEO expressed optimism about the immunology market and highlighted the positive feedback received from the Amelior drug [4][6] - There are ongoing discussions regarding U.S. government policies affecting drug pricing, with uncertainty about how these will impact the industry [7][10] Drug Pipeline and R&D - Sanofi is focusing on the performance of its drugs, particularly Dupixent and Amelior, with expectations of continued growth [20][28] - The company plans to provide more precise guidance on its financial outlook in the upcoming Q3 call, especially regarding R&D spending and P&L evolution [17][19] - The CEO emphasized the importance of maintaining a strong R&D pipeline, with a focus on high-value indications and efficient resource allocation [19][21] Financial Performance and Expectations - Sanofi is experiencing strong growth, with Dupixent showing faster growth rates than in previous years [20][28] - The company is managing its G&A expenses carefully, with high expectations for 2026 [20] - There is a focus on leveraging the P&L effectively, with the CEO acknowledging the need for clearer communication regarding financial expectations [25][26] Regulatory Environment - The FDA is taking a cautious approach to reviewing data for tolibrutinib, with a focus on ensuring the safety and efficacy of treatments for multiple sclerosis [30][31] - The CEO expressed a preference for the FDA to take the necessary time to review data thoroughly rather than rushing to a decision [30][31] Future Outlook - Sanofi is optimistic about the potential of its pipeline, including drugs like Amelior and tolibrutinib, and is preparing for upcoming data readouts that could significantly impact its market position [42][66] - The company is also exploring opportunities in the mRNA space, particularly in partnership with Novavax for COVID and flu vaccines, with potential approvals expected around 2027-2028 [71][73] Additional Insights - The CEO highlighted the importance of addressing the role of Pharmacy Benefit Managers (PBMs) in the pricing conversation and the need for transparency in drug pricing [9][10] - There is a recognition of the challenges faced by the industry, with a call for a more unified approach to regulatory and pricing issues to benefit patients [10][12] This summary captures the essential insights from the Sanofi conference call, focusing on the company's strategic direction, market challenges, and future opportunities.

Vertex Pharmaceuticals Conference Call Summary Company Overview - **Company**: Vertex Pharmaceuticals (NasdaqGS: VRTX) - **Event**: Bank of America Healthcare Conference - **Date**: September 23, 2025 Key Industry and Company Insights Upcoming Catalysts - Vertex is entering a new phase of revenue and commercialization diversification with three ongoing commercial launches: - **LifTrak**: Fifth medicine for cystic fibrosis (CF) - **Casgevy**: For sickle cell disease and beta thalassemia - **Jurnavix**: For acute pain - Four ongoing Phase 3 programs and a fifth to start soon, including: - Diabetic peripheral neuropathy (DPN) - Immunoglobulin A nephropathy (POVI) - Enoxaparin in APOL1-mediated kidney disease - Zomylacell in type 1 diabetes [4][5][6] Cystic Fibrosis (CF) Franchise Growth Drivers - Survival benefits of CFTR modulators are significant, with patients expected to live into their early 80s if treated early. - Ongoing approvals for therapies in younger patients, with LifTrak approved for ages six and up. - Expansion into new geographies, notably Brazil. - LifTrak targets patients with rare mutations not eligible for other therapies, with a potential market of a few thousand in Europe and a few hundred in the U.S. [9][10] LifTrak Adoption and Monitoring - Strong uptake in the U.S. with three patient populations: - Naive patients who have not been on CFTR modulators - Discontinued patients returning for therapy - Patients switching from Trikafta to LifTrak - Additional liver monitoring requirement in the U.S. has led to discussions between physicians and patients regarding the benefits versus monitoring burden [12][13][16] Pricing Strategy and Market Position - Vertex maintains a competitive pricing strategy, with a focus on serious diseases and transformative effects. - The company is well-positioned against peers despite potential challenges from pricing regulations [18][19] Pain Franchise: Jurnavix - Jurnavix has achieved unrestricted access for 150 million lives in the U.S., with 85 million having no prior authorization requirements. - The drug's efficacy and clean side effect profile are key selling points against traditional pain management options like opioids [26][28][31] Kidney Franchise: POVI and IgAN - Vertex's acquisition of Alpine aimed to secure a best-in-class clinical profile for POVI, targeting both BAF and APRIL for better patient outcomes. - The company anticipates a significant market opportunity in IgAN, estimating over 300,000 patients in the U.S. and Europe, with potential expansion into Asia [55][66] Future Directions and Pipeline - Vertex is focused on expanding its renal sales force and enhancing its presence in the kidney disease market. - The company is optimistic about the potential of Zomylacell for type 1 diabetes, which could significantly reduce insulin dependency for patients [73][74] Conclusion - Vertex Pharmaceuticals is positioned for growth with multiple product launches and a robust pipeline across various therapeutic areas, including cystic fibrosis, pain management, and kidney diseases. The company is actively working to address market needs and regulatory challenges while maintaining a focus on innovative therapies that provide transformative benefits to patients.

Financial Data and Key Metrics Changes - The company reported a significant increase in revenue, nearly tripling compared to the previous quarter, largely due to increased operations at the first battery recycling plant [6][7] - For the fiscal year, revenue increased to approximately $4.3 million from about $0.3 million the previous year, indicating a substantial growth [7][21] - Cash balance increased to over $25 million as of September 15, 2025, attributed to increased trading volume and institutional ownership following the addition to the Russell 2000 and 3000 indices [8][20] Business Line Data and Key Metrics Changes - The battery recycling operations saw a 70% increase in throughput in a single quarter, reflecting operational improvements and increased headcount [9] - The primary claystone to lithium hydroxide business is progressing with the construction of a commercial scale facility, with ongoing efforts to secure long-term off-take agreements [18][21] Market Data and Key Metrics Changes - The company has experienced a significant increase in trading volume and institutional ownership since being added to the Russell indices, indicating a shift in investor interest [8][20] - The company is also engaging more with stationary grid battery systems, expanding its market reach beyond automotive batteries [12][13] Company Strategy and Development Direction - The company aims to create a closed-loop battery metal supply chain in North America, focusing on both recycling and primary mineral extraction [4][6] - Plans for a second battery recycling plant are underway, supported by a $144 million grant from the U.S. Department of Energy, indicating a commitment to scaling operations [11][12] - The company is also advancing its lithium hydroxide technologies and has been selected as a transparency priority project to streamline federal permitting processes [18][19] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the growth of the battery industry and the need for both recycling and new mineral extraction to meet demand [5][6] - The company anticipates continued improvements in margins as operations scale and efficiencies are realized [7][21] Other Important Information - The company successfully closed out a project with the U.S. Advanced Battery Consortium, demonstrating the effectiveness of its recycling processes [10] - The company has received competitive tax credits and continues to secure government grants to support its operations [22] Q&A Session Summary Question: What are the expectations for revenue growth moving forward? - Management indicated that revenue growth is expected to continue as operations ramp up and new projects are initiated [21] Question: How is the company addressing the challenges in the battery recycling market? - The company is focusing on operational improvements and scaling its recycling plant to enhance throughput and efficiency [9][21] Question: What is the status of the second battery recycling plant? - The second plant is in the early stages of construction, with lessons learned from the first plant being applied to its development [12][21]

Financial Data and Key Metrics Changes - The company reported a significant increase in revenue, nearly tripling compared to the previous quarter, largely due to increased operations at the first battery recycling plant [6][7] - For the fiscal year, revenue increased to approximately $4.3 million from about $0.3 million the previous year, with a larger relative increase in revenue than in cash cost of goods sold, leading to improved margins [7][21] - Cash balance increased to over $25 million as of September 15, 2025, attributed to increased trading volume and institutional ownership following the company's addition to the Russell 2000 and 3000 indices [9][20] Business Line Data and Key Metrics Changes - The battery recycling business saw a 70% increase in throughput in a single quarter, reflecting operational improvements and increased headcount [10] - The company is also developing a second battery recycling plant, supported by a $144 million grant from the U.S. Department of Energy, indicating growth in both recycling and primary lithium hydroxide production [12][18] Market Data and Key Metrics Changes - The company has experienced a substantial increase in trading volume and institutional ownership since being added to the Russell indices, indicating a shift in investor interest [8][20] - The company is expanding its market reach by working with both automotive and stationary grid battery systems, diversifying its customer base [14] Company Strategy and Development Direction - The company aims to create a closed-loop battery metal supply chain in North America, focusing on both recycling and primary mineral extraction [5][6] - The strategic focus includes scaling operations at the existing recycling plant and developing a commercial-scale lithium hydroxide facility, with ongoing efforts to streamline federal permitting processes [18][19] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the growth of the battery industry and the company's ability to meet increasing demand through improved operations and strategic partnerships [6][12] - The company highlighted the importance of domestic lithium manufacturing and recycling in supporting critical infrastructure, including data centers and supercomputers [15][16] Other Important Information - The company has successfully closed out several projects funded by government grants, demonstrating compliance with grant requirements and operational capabilities [11][17] - The company has received a letter of interest from the U.S. Export-Import Bank for a $900 million low-interest loan to support its lithium project, indicating strong governmental support [20] Q&A Session Summary Question: What are the expectations for revenue growth moving forward? - Management indicated that revenue growth is expected to continue as operations scale and new projects ramp up, with a focus on improving margins [21] Question: How is the company addressing the challenges in the battery recycling market? - The company is enhancing operational efficiencies and expanding its recycling capabilities to meet the growing demand for battery materials [6][10] Question: What is the status of the second battery recycling plant? - The second plant is under construction, supported by a significant grant, and is expected to leverage lessons learned from the first plant to optimize operations [12][18]

Financial Data and Key Metrics Changes - Revenue increased by 70% from $8.4 million in H1 2024 to $14.3 million in H1 2025, primarily due to the monetization of the ride-hailing service [18] - Adjusted EBITDA improved by $5.4 million from negative $11.3 million in H1 2024 to negative $6 million in H1 2025 [20] - Cost of revenues decreased by 25% from $9.9 million in H1 2024 to $7.4 million in H1 2025 [18][19] Business Line Data and Key Metrics Changes - Unique ride-hailing riders grew from 1.1 million to 2.3 million year-over-year in H1 2025, a 107% increase [11] - Registered ride-hailing drivers increased from 171,000 to 327,000, a 92% year-over-year growth [11] - Total rides increased from 13.7 million in H1 2024 to 19.2 million in H1 2025 [17] Market Data and Key Metrics Changes - The company expanded its operations into six new metropolitan areas, increasing its reach to 10 cities, covering approximately half of Türkiye's population [7][8] - The share of riders based outside Istanbul grew from 13% to 24% over the last year, indicating strong demand in new markets [36] Company Strategy and Development Direction - The company is focusing on ride-hailing as its primary strategic direction, with plans to capture a $3 billion annual revenue opportunity in the ride-hailing market [12] - Investments are being made in building organizational capabilities, including AI engineering and performance marketing, to enhance operational efficiency and market position [9][10] - The company aims to reach 3.3 million riders and 450,000 registered drivers by the end of 2025 [11] Management's Comments on Operating Environment and Future Outlook - Management believes 2025 will be pivotal for scale and financial performance, with expectations to nearly double revenue from $18.7 million in 2024 to $34 million in 2025 [5][20] - The company is optimistic about the demand for ride-hailing services in Türkiye, especially in cities that have not previously experienced tech-based mobility solutions [34][35] Other Important Information - The company is the largest electric vehicle operator in Türkiye and the number one urban mobility app on both iOS and Android platforms [6] - The average App Store rating is 4.9 out of 5, reflecting positive user sentiment and engagement [10] Q&A Session Summary Question: What is the target level for two-wheeled electric vehicles deployed? - Management indicated that two-wheeled electric vehicles are integral to the service offering and will be reevaluated in summer 2026 based on customer needs and traffic to ride-hailing [22][23][24] Question: How is driver supply and AI engineering impacting the business? - There are no constraints in onboarding additional drivers, with driver supply increasing year-over-year. AI engineering is critical for optimizing pricing and enhancing rider and driver experiences [26][29] Question: What are the current take rates compared to global benchmarks? - Current take rates are in the high single digits, with significant upside potential for future increases [33] Question: How does the company balance growth and profitability? - The company is focused on growth while maintaining low take rates to capture market share, with plans to reassess the balance between fundraising and take rates in the future [42][64] Question: What is the strategy regarding the regulatory environment in Türkiye? - The company believes it is uniquely positioned to introduce and regulate new transportation services in Türkiye [48] Question: How does the company view its crypto treasury strategy? - The crypto strategy is designed to diversify non-operating cash, primarily held in USD, with a small fraction in Bitcoin as a store of value [50][51]

Financial Data and Key Metrics Changes - Revenue increased by 70% from $8.4 million in the first half of 2024 to $14.3 million in the first half of 2025, primarily due to the monetization of the ride-hailing service [18] - Adjusted EBITDA improved by $5.4 million from negative $11.3 million in the first half of 2024 to negative $6 million in the first half of 2025 [20] - Cost of revenues decreased by 25% from $9.9 million in the first half of 2024 to $7.4 million in the first half of 2025 [18][19] Business Line Data and Key Metrics Changes - Unique ride-hailing riders increased from 1.1 million to 2.3 million year-over-year in the first half of 2025, a growth of 107% [11] - Registered ride-hailing drivers grew by 92% year-over-year, from 171,000 to 327,000 [11] - Total rides increased from 13.7 million in the first half of 2024 to 19.2 million in the first half of 2025 [17] Market Data and Key Metrics Changes - The company expanded its operations into six additional metropolitan areas, bringing its total to ten cities, which represent approximately half of Türkiye's population and nearly two-thirds of its GDP [7][8] - The share of riders based outside of Istanbul grew from 13% to 24% over the last year, indicating strong demand in new markets [36] Company Strategy and Development Direction - The company is focusing on ride-hailing as its primary strategic direction, with plans to capture an estimated $3 billion annual revenue opportunity in the ride-hailing business [12] - Investments are being made in building organizational capabilities to support rapid growth in ride-hailing, including the introduction of new departments such as AI engineering and performance marketing [9][10] - The company aims to reach 3.3 million riders and 450,000 registered drivers by the end of 2025 [11] Management's Comments on Operating Environment and Future Outlook - Management believes that 2025 will be a pivotal year for scale and financial performance, with strong revenue growth and significant improvement in adjusted EBITDA [4] - The company is optimistic about the demand for ride-hailing services in Türkiye, especially in secondary cities that have not previously experienced tech-based mobility solutions [34][35] - The management is confident in the operational advantages of local companies in the mobility market, which enhances their competitive position [7] Other Important Information - The company has served over 128.6 million rides to 6.4 million unique riders since its launch [6] - The average App Store rating is 4.9 out of 5, reflecting positive user sentiment [10] - The company has raised an additional convertible note financing of $23 million in April, which fully funds the growth of the business for the next 12 months [64] Q&A Session Summary Question: What is the target level for two-wheeled electric vehicles deployed? - Management believes two-wheeled electric vehicle operations are integral to their service offering and will reevaluate the fleet size in summer 2026 [23][24] Question: How is driver supply and AI engineering impacting the business? - There are no constraints in onboarding additional drivers, and the AI engineering team is critical for optimizing pricing and enhancing rider and driver experiences [26][29] Question: What are the current take rates compared to global benchmarks? - Current take rates are in the high single digits, with significant upside potential for future increases [33] Question: How does the company balance growth and profitability? - The company is focused on growth while maintaining low take rates to capture market share, with plans to optimize profitability as the market matures [42] Question: What is the regulatory environment for ride-hailing in Türkiye? - The company believes it is well-positioned to introduce and regulate new transportation services in Türkiye [48] Question: What is the strategy regarding crypto treasury? - The company is diversifying its non-operating cash into USD and Bitcoin as a store of value, while the majority remains in USD [51] Question: What are the unit economics for rider and driver incentives? - Rider and driver incentives are limited, with low acquisition costs due to the existing brand presence and user base [56]